Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript

Core Insights - Zai Lab is conducting a 2025 Triple Meeting Investor Call to discuss its global asset portfolio and clinical data updates [1][2] - The agenda includes an overview of the global asset portfolio, detailed presentation of updated clinical data for Zoci, and future steps for the program [3] Company Overview - Zai Lab focuses on oncology and immunology as its two core areas for global development [4] - The company is highlighting its growing global innovation pipeline, particularly emphasizing Zoci as a potential first and best-in-class DLL3 targeted therapy [4]